[1] HUANG HL, HUANG WC, LIN KD, et al.Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study[J]. Clin Infect Dis, 2021, 73(6): e1252-e1260. [2] NJIE GJ, MORRIS SB, WOODRUFF RY, et al.Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis[J]. Am J Prev Med, 2018, 55(2): 244-252. [3] CHANG A, WU CZ, LIN JD, et al.Prevalence and risk factors for latent tuberculosis among diabetes patients in Taiwan: A cross-sectional study[J]. J Infect Dev Ctries, 2022, 16(4): 644-649. [4] GAO L, BAI L, LIU J, et al.Annual risk of tuberculosis infection in rural China: a population-based prospective study[J]. Eur Respir J, 2016, 48(1): 168-178. [5] HOUBEN RM, DODD PJ.The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling[J]. PLoS Med, 2016, 13(10): e1002152. [6] 桂静, 杨慧, 傅钰, 等. 血糖血脂异常对肺结核合并2型糖尿病的影响分析[J/CD]. 新发传染病电子杂志, 2022, 7(4): 37-41. [7] 杨松, 严晓峰. 结核病与糖尿病:相互关系和诊治的研究新进展[J/CD]. 新发传染病电子杂志, 2018, 3(4): 234-238. [8] AL-RIFAI RH, PEARSON F, CRITCHLEY JA, et al.Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(11): e0187967. [9] BAGHAEI P, MARJANI M, JAVANMARD P, et al.Diabetes mellitus and tuberculosis facts and controversies[J]. J Diabetes Metab Disord, 2013, 12(1): 58. [10] PING PA, ZAKARIA R, ISLAM MA, et al.World Health Organization. Framework for collaborative action on tuberculosis and comorbidities[J]. J Infect Dev Ctries, 2022, 87(1):25-31. [11] MAGEE MJ, KHAKHARIA A, GANDHI NR, et al.Increased Risk of Incident Diabetes Among Individuals With Latent Tuberculosis Infection[J]. Diabetes Care, 2022, 45(4): 880-887. [12] BARRON MM, SHAW KM, BULLARD KM, et al.Diabetes is associated with increased prevalence of latent tuberculosis infection: Findings from the National Health and Nutrition Examination Survey, 2011-2012[J]. Diabetes Res Clin Pract, 2018, 139: 366-379. [13] MARTINEZ-AGUILAR G, SERRANO CJ, CASTANEDA-DELGADO JE, et al.Associated Risk Factors for Latent Tuberculosis Infection in Subjects with Diabetes[J]. Arch Med Res, 2015, 46(3): 221-227. [14] LIN CH, KUO SC, HSIEH MC, et al.Effect of diabetes mellitus on risk of latent TB infection in a high TB incidence area: a community-based study in Taiwan[J]. BMJ Open, 2019, 9(10): e029948. [15] ODONE A, HOUBEN RM, WHITE RG, et al.The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets[J]. Lancet Diabetes Endocrinol, 2014, 2(9): 754-764. [16] VINEY K, CAVANAUGH J, KIENENE T, et al.Tuberculosis and diabetes mellitus in the Republic of Kiribati: a case-control study[J]. Trop Med Int Health, 2015, 20(5):650-657. [17] AYELIGN B, NEGASH M, GENETU M, et al.Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis[J]. J Immunol Res, 2019, 2019: 6196532. [18] MARTINEZ N, KORNFELD H.Diabetes and immunity to tuberculosis[J]. Eur J Immunol, 2014, 44(3): 617-626. [19] RESTREPO BI, SCHLESINGER LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus[J]. Tuberculosis (Edinb), 2013, Suppl(0): S10-S14. [20] LIU Q, YAN W, LIU R, et al.The Association Between Diabetes Mellitus and the Risk of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis[J]. Front Med (Lausanne), 2022, 9: 899821. [21] LEE MR, HUANG YP, KUO YT, et al.Diabetes Mellitus and Latent Tuberculosis Infection: A Systematic Review and Metaanalysis[J]. Clin Infect Dis, 2017, 64(6): 719-727. [22] TEPEKULE B, KUSEJKO K, ZEEB M, et al.Impact of Latent Tuberculosis on Diabetes[J]. J Infect Dis, 2022, 225(12): 2229-2234. [23] RONALD LA, CAMPBELL JR, ROSE C, et al.Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study[J]. Clin Infect Dis, 2019, 69(12): 2101-2108. [24] LIN Y, HARRIES AD, KUMAR AMV, et al.Tackling diabetes mellitus and tuberculosis: a new Union guide on the management of diabetes-tuberculosis[J]. Int J Tuberc Lung Dis, 2019, 23(7): 771-772. [25] 李相威, 金奇, 高磊. 我国结核分枝杆菌潜伏感染流行现状[J/CD]. 新发传染病电子杂志, 2017, 2(3): 146-150. [26] MAZUREK GH, JEREB J, VERNON A, et al.Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010[J]. MMWR Recomm Rep, 2010, 59(RR-5): 1-25. [27] 中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识[J]. 中国防痨杂志, 2020, 42(8): 761-768. [28] LARGEN A, AYALA A, KHURANA R, et al.Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection[J]. Int J Tuberc Lung Dis, 2021, 25(7): 547-553. [29] SINGHAL A, JIE L, KUMAR P, et al. Metformin as adjunct antituberculosis therapy[J]. Sci Transl Med, 2014, 6(263): 263ra159. [30] MAGEE MJ, SALINDRI AD, KORNFELD H, et al.Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins[J]. Eur Respir J, 2019, 53(3):1801695. [31] SU VY, SU WJ, YEN YF, et al.Statin Use Is Associated With a Lower Risk of TB[J]. Chest, 2017, 152(3): 598-606. [32] PADMAPRIYADARSINI C, BHAVANI PK, NATRAJAN M, et al.Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial[J]. BMJ Open, 2019, 9(3): e024363. [33] TSENG CH.Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients[J]. J Clin Med, 2018, 7(9):264. [34] LEE MC, CHIANG CY, LEE CH, et al.Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria[J]. PLoS One, 2018, 13(10): e0205807. [35] LIN SY, TU HP, LU PL, et al.Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes[J]. Respirology, 2018, 23(11): 1063-1073. [36] VASHISHT R, BRAHMACHARI SK.Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis[J]. J Transl Med, 2015, 13: 83. [37] LACHMANDAS E, ECKOLD C, BOHME J, et al.Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects[J]. J Infect Dis, 2019, 220(1): 139-150. [38] 谭运彩, 袁媛, 杨双喜, 等. 二甲双胍与2型糖尿病患者肺结核感染风险的倾向性评分匹配分析[J/CD]. 新发传染病电子杂志, 2021, 6(3): 202-205. [39] 徐新月, 赵晓龙. 结核病与糖尿病共病的药物治疗进展[J/CD]. 新发传染病电子杂志, 2023, 8(2): 74-77. [40] MEREGILDO-RODRIGUEZ ED, CHUNGA-CHEVEZ EV, GIANMARCO RL, et al.Further insights into to the role of statins against active tuberculosis: systematic review and meta-analysis[J]. Infez Med, 2022, 30(2): 194-203. [41] TSAI IF, KUO CP, LIN AB, et al.Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes[J]. Respirology, 2017, 22(3): 559-566. [42] HUYNH KK, GERSHENZON E, GRINSTEIN S.Cholesterol accumulation by macrophages impairs phagosome maturation[J]. J Biol Chem, 2008, 283(51): 35745-35755. [43] YAMAMURA T, OHSAKI Y, SUZUKI M, et al.Inhibition of Niemann-Pick-type C1-like1 by ezetimibe activates autophagy in human hepatocytes and reduces mutant alpha1-antitrypsin Z deposition[J]. Hepatology, 2014, 59(4): 1591-1599. [44] LEE PH, LIN HC, HUANG AS, et al.Diabetes and risk of tuberculosis relapse: nationwide nested case-control study[J]. PLoS One, 2014, 9(3): e92623. [45] 杨敏, 付亮, 邓国防. 结核病并发糖尿病治疗管理相关进展[J]. 中国防痨杂志, 2021, 43(1): 87-90. [46] SUREKHA V, PETER JV, JEYASEELAN L, et al.Drug interaction: rifampicin and glibenclamide[J]. Natl Med J India, 1997, 10(1): 11-12. [47] JAAKKOLA T, BACKMAN JT, NEUVONEN M, et al.Effect of rifampicin on the pharmacokinetics of pioglitazone[J]. Br J Clin Pharmacol, 2006, 61(1): 70-78. [48] NIEMI M, KIVISTO KT, BACKMAN JT, et al.Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride[J]. Br J Clin Pharmacol, 2000, 50(6): 591-595. [49] 张霞, 汤泓. 上海市长宁区老年糖尿病患者结核潜伏感染现况和预防性治疗态度[J]. 中国热带医学, 2021, 21(5): 408-412. [50] 艾静文, 阮巧玲, 张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展[J]. 中国防痨杂志, 2015, 37(1): 80-85. [51] JUNG YEG, SCHLUGER NW.Advances in the diagnosis and treatment of latent tuberculosis infection[J]. Curr Opin Infect Dis, 2020, 33(2): 166-172. [52] 中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志, 2021, 43(9): 874-878. |